Systematic review: Caspase-cleaved fragments of cytokeratin 18 - The promises and challenges of a biomarker for chronic liver disease

Alimentary Pharmacology and Therapeutics

Volumn 30, Issue 11-12, 2009, Pages 1103-1109

  Yilmaz, Y ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 18;

ALCOHOL LIVER DISEASE; APOPTOSIS; CHOLESTASIS; CHRONIC LIVER DISEASE; DIAGNOSTIC VALUE; FATTY LIVER; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; REVIEW; SCREENING; SYSTEMATIC REVIEW; VIRUS HEPATITIS;

APOPTOSIS; BIOLOGICAL MARKERS; CASPASES; HUMANS; KERATIN-18; LIVER; LIVER DISEASES;

EID: 70350747448     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04148.x     Document Type: Review

References (33)

1. Najimi M, Smets F, Sokal E. Hepatocyte apoptosis. Methods Mol Biol 2009 481 : 59 74.
2. Linder S, Havelka AM, Ueno T, Shoshan MC. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett 2004 214 : 1 9.
3. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut 2005 54 : 1024 1033.
4. Caulín C, Salvesen GS, Oshima RG. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 1997 138 : 1379 1394.
5. Oshima RG. Apoptosis and keratin intermediate filaments. Cell Death Differ 2002 9 : 486 492.
6. Kramer G, Erdal H, Mertens HJ, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004 64 : 1751 1756.
7. Luft T, Conzelmann M, Benner A, et al. Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood 2007 110 : 4535 4542.
8. Linder S. Cytokeratin markers come of age. Tumour Biol 2007 28 : 189 195.
9. Kakehashi A, Inoue M, Wei M, Fukushima S, Wanibuchi H. Cytokeratin 8/18 overexpression and complex formation as an indicator of GST-P positive foci transformation into hepatocellular carcinomas. Toxicol Appl Pharmacol 2009 238 : 71 9.
10. Gonzalez-Quintela A, Mallo N, Mella C, et al. Serum levels of cytokeratin-18 (tissue polypeptide-specific antigen) in liver diseases. Liver Int 2006 26 : 1217 1224. (Pubitemid 44741209)
11. Yagmur E, Trautwein C, Leers MP, Gressner AM, Tacke F. Elevated apoptosis-associated cytokeratin 18 fragments (CK18Asp386) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammation. Clin Biochem 2007 40 : 651 655.
12. Bantel H, Lügering A, Heidemann J, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004 40 : 1078 1087.
13. Yilmaz Y, Dolar E, Ulukaya E, et al. Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C. Med Sci Monit 2009 15 : CR189 93.
14. Feldstein A, Kleiner D, Kravetz D, Buck M. Severe hepatocellular injury with apoptosis induced by a hepatitis C polymerase inhibitor. J Clin Gastroenterol 2009 43 : 374 381.
15. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, et al. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut 2008 57 : 500 506.
16. Gonzalez-Quintela A, García J, Campos J, et al. Serum cytokeratins in alcoholic liver disease: contrasting levels of cytokeratin-18 and cytokeratin-19. Alcohol 2006 38 : 45 9.
17. Gonzalez-Quintela A, Abdulkader I, Campos J, Fernandez-Hernandez L, Lojo S. Serum levels of keratin-18 fragments [tissue polypeptide-specific antigen (TPS)] are correlated with hepatocyte apoptosis in alcoholic hepatitis. Dig Dis Sci 2009 54 : 648 653.
18. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006 44 : 27 33.
19. Yilmaz Y, Dolar E, Ulukaya E, et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007 13 : 837 844.
20. Yilmaz Y, Ulukaya E, Dolar E. Serum M30 levels: a potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels. Hepatology 2009 49 : 697.
21. Diab DL, Yerian L, Schauer P, Kashyap SR, Lopez R, et al. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol 2008 6 : 1249 1254.
22. Vos MB, Barve S, Joshi-Barve S, Carew JD, Whitington PF, McClain CJ. Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2008 47 : 481 485.
23. Younossi ZM, Jarrar M, Nugent C, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008 18 : 1430 1437.
24. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009 50 : 1072 1078.
25. Malik R, Chang M, Bhaskar K, et al. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2009 24 : 564 568.
26. Simopoulos C, Tsaroucha AK, Asimakopoulos B, et al. Total and caspase-cleaved cytokeratin 18 in chronic cholecystitis: a prospective study. BMC Gastroenterol 2008 8 : 14.
27. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005 115 : 209 218.
28. Tarantino G, Conca P, Coppola A, Vecchione R, Di Minno G. Serum concentrations of the tissue polypeptide specific antigen in patients suffering from non-alcoholic steatohepatitis. Eur J Clin Invest 2007 37 : 48 53.
29. Valva P, De Matteo E, Galoppo M, et al. Apoptosis markers in liver biopsy of nonalcoholic steatohepatitis in pediatric patients. Hum Pathol 2008 39 : 1816 1822.
30. Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 2000 9 : 235 251.
31. Denzer UW, Lüth S. Non-invasive diagnosis and monitoring of liver fibrosis and cirrhosis. Best Pract Res Clin Gastroenterol 2009 23 : 453 460.
32. Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem 2008 54 : 17 23.
33. Poynard T, Ratziu V, Benhamou Y, Thabut D, Moussalli J. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy? Gastroenterology 2005 128 : 1146 1148.